Introduction: The high failure rate of industry-driven pediatric clinical trials leads to insufficient timely labeling of drugs in children and a lack of scientific evidence, resulting in the persistently high off-label drug use. National clinical trial networks can facilitate collaboration between sites, investigators, and experts, increasing the likelihood of successful trials. Within the conect4children (c4c) network,…
Paediatric clinical trials are critical to ensure that medications prescribed to children are safe and effective. However, evidence-based dosing and labelling of such medications remain limited, and most clinical trials in paediatrics fail. Factors for lack of trial completion include performance at site level (limited patient recruitment, limited site staff experience and lack of infrastructure),…
Paediatric clinical trials are critical to ensure that medications prescribed to children are safe and effective. However, evidence-based dosing and labelling of such medications remain limited, and most clinical trials in paediatrics fail. Factors for lack of trial completion include performance at site level (limited patient recruitment, limited site staff experience and lack of infrastructure),…
Fundamental steps in the development of the Czech National Hub began more systematically in 2019. Since then, the Hub has been involved in several national paediatric research projects.
One year of the no-cost extension of the c4c project has been approved by IHI (Innovative Health Initiative), so the new end date of the project is 30/04/2025.
Meet the team behind c4c! We are a diverse group of people from many different backgrounds, all working towards a common goal: better medicines for children through European clinical trials. Today’s spotlight is on Ricardo Fernandes, from the University of Lisbon and AIDFM.
Defining how meaningful Patient and Public Involvement (PPI) is realised in practice, (especially where child and young patients are concerned) is limited partly due to the low-level reporting of the processes and outputs of PPI activities in general.
At the end of a year which brought a lot of change and uncertainty to the world around us, we would like to reflect on c4c´s achievements of the past year and to look forward to what lies ahead in the coming months.
Patent ductus arteriosus (PDA) in preterm infants is associated with increased morbidities and mortality. Prophylactic treatment with cyclooxygenase inhibitors, as indomethacin or ibuprofen, failed to demonstrate significant clinical benefits. Acetaminophen may represent an alternative treatment option. To read full article, click here
